Drug Trial Radar · NCT05018299
Evaluate the Efficacy and Safety of FB704A in Adult With Severe Asthma
Last checked: Nov 19, 2026Latest source record: Jul 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
21
Actual
Start
Sep 30, 2021
Primary completion
May 8, 2026
Study completion May 8, 2026
Sponsor
- Lead sponsor
- Oneness Biotech Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 24, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, placebo controlled and double blind study to evaluate the safety, tolerability, pharmacokinetics, and clinical activity of FB704A in adult patients with severe asthma. The study comprised a 4-week screening period, a 8-week treatment period and a 12-week follow-up period.
Conditions
- Severe Asthma
Interventions
FB704A placeboBiological
Placebo
FB704ABiological
Anti-IL-6 antibody
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of the number of Adverse Event reported during the treatment periodTime frame: Day 57
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Kaohsiung Chang Gung Memorial Hospital
Kaohsiung City, Taiwan
China Medical University Hospital
Taichung, Taiwan
Taichung Veterans General Hospital
Taichung, Taiwan
National Taiwan University Hospital
Taipei, Taiwan
Taipei Medical University Hospital
Taipei, Taiwan
Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare
Taipei, Taiwan
Taipei Municipal Wanfang Hospital
Taipei, Taiwan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.